NO984757D0 - Gliacellelinjeavledet, neurotropisk faktorreseptor - Google Patents

Gliacellelinjeavledet, neurotropisk faktorreseptor

Info

Publication number
NO984757D0
NO984757D0 NO984757A NO984757A NO984757D0 NO 984757 D0 NO984757 D0 NO 984757D0 NO 984757 A NO984757 A NO 984757A NO 984757 A NO984757 A NO 984757A NO 984757 D0 NO984757 D0 NO 984757D0
Authority
NO
Norway
Prior art keywords
gdnf
gdnfr
receptor
glial cell
found
Prior art date
Application number
NO984757A
Other languages
English (en)
Other versions
NO984757L (no
Inventor
Gary M Fox
Shuqian Jing
Duanzhi Wen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO984757D0 publication Critical patent/NO984757D0/no
Publication of NO984757L publication Critical patent/NO984757L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
NO984757A 1996-04-22 1998-10-12 Gliacellelinjeavledet, neurotropisk faktorreseptor NO984757L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1590796P 1996-04-22 1996-04-22
US1722196P 1996-05-09 1996-05-09
US08/837,199 US6455277B1 (en) 1996-04-22 1997-04-14 Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
PCT/US1997/006281 WO1997040152A1 (en) 1996-04-22 1997-04-15 Glial cell line-derived neurotrophic factor receptor

Publications (2)

Publication Number Publication Date
NO984757D0 true NO984757D0 (no) 1998-10-12
NO984757L NO984757L (no) 1998-12-21

Family

ID=27360445

Family Applications (1)

Application Number Title Priority Date Filing Date
NO984757A NO984757L (no) 1996-04-22 1998-10-12 Gliacellelinjeavledet, neurotropisk faktorreseptor

Country Status (19)

Country Link
US (3) US6455277B1 (no)
EP (1) EP0909316B1 (no)
JP (1) JP2000509271A (no)
KR (1) KR20000010571A (no)
CN (1) CN1219967A (no)
AT (1) ATE338115T1 (no)
AU (1) AU720092B2 (no)
BR (1) BR9708959A (no)
CA (1) CA2250704C (no)
CZ (1) CZ324598A3 (no)
DE (1) DE69736597T2 (no)
EA (1) EA002924B1 (no)
ES (1) ES2271968T3 (no)
HU (1) HUP9902640A3 (no)
IL (1) IL126553A0 (no)
NO (1) NO984757L (no)
NZ (1) NZ332256A (no)
SK (1) SK140398A3 (no)
WO (1) WO1997040152A1 (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696259B1 (en) * 1995-11-13 2004-02-24 Licentia Ltd. Assays using glial cell line-derived neurotrophic factor receptors
US6677135B1 (en) * 1996-05-08 2004-01-13 Biogen, Inc. Ret ligand (RetL) for stimulating neutral and renal growth
EE9800377A (et) * 1996-05-08 1999-04-15 Biogen, Incorporated Ret-i ligand (RetL) närvi- ja neerukasvu stimuleerimiseks
US20020068361A1 (en) * 1997-04-08 2002-06-06 Douglas Clary Methods of evaluating specific cellular functions of receptor protein tyrosine kinases in a ligand independent manner
CA2291608C (en) * 1997-05-30 2004-04-13 Amgen Inc. Neurotrophic factor receptors
US20010003580A1 (en) 1998-01-14 2001-06-14 Poh K. Hui Preparation of a lipid blend and a phospholipid suspension containing the lipid blend
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
FI20000394A0 (fi) * 2000-02-21 2000-02-21 Airaksinen Matti GFRa4:n sukuisia tai siitä johdettuja aineita sekä niiden käyttö
EA010055B1 (ru) 2003-03-19 2008-06-30 Байоджен Айдек Ма Инк. ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА, КОДИРУЮЩАЯ ПОЛИПЕПТИД Sp35, ПОЛИПЕПТИД Sp35 И СПОСОБЫ ПРИМЕНЕНИЯ НУКЛЕИНОВОЙ КИСЛОТЫ И ПОЛИПЕПТИДА
US20060239966A1 (en) * 2003-10-20 2006-10-26 Tornoee Jens In vivo gene therapy of parkinson's disease
KR101239542B1 (ko) 2004-06-24 2013-03-07 바이오겐 아이덱 엠에이 인코포레이티드 탈수초화를 수반하는 병의 치료
EP1807506B1 (en) * 2004-10-08 2013-04-17 Georgia Tech Research Corporation Microencapsulation of cells in hydrogels using electrostatic potentials
WO2007008547A2 (en) 2005-07-08 2007-01-18 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
US20090246189A1 (en) * 2005-11-04 2009-10-01 Biogen Idec Ma Inc. And Mclean Hospital Methods for Promoting Neurite Outgrowth and Survival of Dopaminergic Neurons
NZ590605A (en) 2008-07-09 2012-11-30 Biogen Idec Inc Compositions comprising antibodies to lingo or fragments thereof
MX2014013950A (es) 2012-05-14 2015-02-17 Biogen Idec Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
EP3242893A1 (en) 2015-01-08 2017-11-15 Biogen MA Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
EP3538560A4 (en) 2016-11-10 2020-06-17 Keros Therapeutics, Inc. GDNF FUSION POLYPEPTIDES AND METHODS OF USE
RU2690498C1 (ru) * 2018-05-17 2019-06-04 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр" Способ получения ноотропной композиции на основе полипептидных комплексов, выделенных из нейронов и глиальных клеток, полученных методом направленной дифференцировки индуцированных плюрипотентных стволовых клеток человека
RU2732600C1 (ru) * 2019-12-26 2020-09-21 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр имени академика Н.П. Бочкова" Ноотропная композиция на основе полипептидных комплексов, выделенных из нейрональных прогениторных клеток в условиях гипоксии, и способ ее получения
RU2752906C2 (ru) * 2019-12-26 2021-08-11 Федеральное государственное бюджетное научное учреждение "Медико-генетический научный центр имени академика Н.П. Бочкова" Ноотропная композиция на основе полипептидных комплексов, выделенных из нейрональных прогениторных клеток в условиях теплового шока, и способ ее получения

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
WO1990006952A1 (en) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
JP2877509B2 (ja) 1989-05-19 1999-03-31 アムジエン・インコーポレーテツド メタロプロテイナーゼ阻害剤
EP1243652A3 (en) 1991-09-20 2003-03-26 Amgen Inc., Glial derived neurotrophic factor
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods

Also Published As

Publication number Publication date
US6455277B1 (en) 2002-09-24
BR9708959A (pt) 1999-08-03
ATE338115T1 (de) 2006-09-15
CA2250704C (en) 2005-04-12
AU2730997A (en) 1997-11-12
NZ332256A (en) 2000-03-27
US20030175876A1 (en) 2003-09-18
AU720092B2 (en) 2000-05-25
EA199800933A1 (ru) 1999-04-29
IL126553A0 (en) 1999-08-17
SK140398A3 (en) 1999-04-13
EP0909316B1 (en) 2006-08-30
DE69736597T2 (de) 2006-12-21
ES2271968T3 (es) 2007-04-16
DE69736597D1 (de) 2006-10-12
HUP9902640A2 (hu) 1999-11-29
EA002924B1 (ru) 2002-10-31
JP2000509271A (ja) 2000-07-25
NO984757L (no) 1998-12-21
KR20000010571A (ko) 2000-02-15
US20060166325A1 (en) 2006-07-27
WO1997040152A1 (en) 1997-10-30
EP0909316A1 (en) 1999-04-21
HUP9902640A3 (en) 2001-11-28
CZ324598A3 (cs) 1999-01-13
CA2250704A1 (en) 1997-10-30
CN1219967A (zh) 1999-06-16

Similar Documents

Publication Publication Date Title
NO984757D0 (no) Gliacellelinjeavledet, neurotropisk faktorreseptor
Bennett et al. Chemical cross-linking with thiol-cleavable reagents combined with differential mass spectrometric peptide mapping—a novel approach to assess intermolecular protein contacts
WO1997033995A3 (en) Extracellular matrix signalling molecules
DK1179067T3 (da) Neurobeskyttende egenskaber hos GDF-15, et medlem af TGF-beta-superfamilien
WO1998006048A3 (en) Molecular modelling of neurotrophin-receptor binding
WO1998054213A3 (en) Neurotrophic factor receptors
WO2002004523A3 (en) Artificial antibody polypeptides
IL195337A0 (en) Cyr61 compositions and methods
CA2471762A1 (en) Cell-permeable peptide inhibitors of the jnk signal transduction pathway
DE69732631D1 (de) Metabotropische gaba(b) rezeptoren, rezeptoren-spezifische liganden und deren anwendungen
Fernández et al. Membrane fractionation of a β-lactoglobulin tryptic digest: Effect of the pH
AU3143897A (en) Oligonucleotides which specifically bind retroviral nucleocapsid proteins
WO2000034475A3 (en) Grnf4, a gdnf-related neurotrophic factor
Kondo et al. Coexpression of GABAA receptor γ1 and γ2 subunits in the rat trigeminal ganglion
Pedrotti et al. Purified native microtubule associated protein MAP1A: kinetics of microtubule assembly and MAP1A/tubulin stoichiometry
Berot et al. Ultrafiltration to fractionate wheat polypeptides
CA2487779A1 (en) P53 binding t cell receptor molecules and uses thereof
WO1998054213B1 (en) Neurotrophic factor receptors
Holder et al. Quantification of bio-and techno-functional peptides in tryptic bovine micellar casein and β-casein hydrolysates
Mizuno et al. Localization of molecules involved in cytokine receptor signaling in the rat trigeminal ganglion
WO2001087932A3 (en) Seven transmembrane proteins and polynucleotides encoding the same
Wang et al. Action of peptidases in brain synaptic membranes on the NH2-terminus of adrenocorticotropin using ACTH-(1–16)-NH2 as a model substrate
WO2002050273A3 (en) A transmembrane protein as a downstream target of neurotrophin and ephrin receptor tyrosine kinases, dna encoding same monoclonal antibodies thereto
WO2021222339A3 (en) De novo designed alpha-helical protein channels
WO2001098360A3 (en) Gp354 nucleic acids and polypeptides

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application